Procedure for Drug Release Testing in Transdermal Patches
1) Purpose
The purpose of this SOP is to outline the procedure for testing the drug release from transdermal patches to ensure consistent and controlled delivery of active pharmaceutical ingredients (APIs).
2) Scope
This SOP applies to all transdermal patches requiring drug release testing as part of quality control measures to assess product performance and adherence to specifications.
3) Responsibilities
Quality Control (QC) Department: Responsible for performing drug release testing.
Quality Assurance (QA) Department: Responsible for review and approval of drug release testing procedures and results.
Manufacturing Department: Responsible for providing transdermal patch samples and support during testing.
4) Procedure
4.1 Sample Preparation:
4.1.1 Cut transdermal patch samples into appropriate sizes for testing.
4.1.2 Remove backing layers to expose the adhesive surface.
4.2 Test Apparatus Setup:
4.2.1 Place the transdermal patch sample onto a receptor compartment of a suitable diffusion cell.
4.2.2 Ensure the receptor compartment is filled with an appropriate receptor fluid to mimic skin conditions.
4.3 Drug Release Testing:
4.3.1 Start the test by maintaining constant temperature and agitation conditions.
4.3.2 Collect samples from the receptor compartment at specified time intervals.
4.3.3 Analyze collected samples for drug content using validated analytical methods.
4.4 Calculation of Drug Release:
4.4.1 Calculate cumulative drug release over time intervals.
4.4.2 Plot drug release profile and determine key parameters such as release rate and total release percentage.
4.4.3 Compare drug release kinetics against acceptance criteria.
4.5 Data Recording:
4.5.1 Record drug release test parameters, including sampling times, drug concentrations, and calculations.
4.5.2 Document any deviations from expected drug release profiles or specifications.
4.6 Reproducibility Testing:
4.6.1 Repeat drug release testing using additional transdermal patch samples to confirm consistency.
4.6.2 Ensure agreement in drug release profiles across multiple tests.
4.7 Reporting:
4.7.1 Prepare a Drug Release Testing Report summarizing test procedures, results, and conclusions.
4.7.2 Include any corrective actions or recommendations based on drug release testing findings.
4.7.3 Submit the report to QA for review and approval and maintain records as per facility procedures.
5) Abbreviations, if any
QC: Quality Control
QA: Quality Assurance
6) Documents, if any
Drug Release Testing Report
Analytical Data
Sample Testing Records
7) Reference, if any
USP (insert appropriate reference for transdermal patches)
FDA Guidance for Industry – Container Closure Systems for Packaging Human Drugs and Biologics
8) SOP Version
Version 1.0
